EMEA-000170-PIP02-10-M03

Key facts

Invented name
Revolade
Active substance
Eltrombopag
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0070/2019
PIP number
EMEA-000170-PIP02-10-M03
Pharmaceutical form(s)
  • Powder for oral suspension
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of secondary thrombocytopenia
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating